University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
South Texas Veterans Health Care System, San Antonio, TX, USA.
Leuk Lymphoma. 2024 Aug;65(8):1090-1099. doi: 10.1080/10428194.2024.2338856. Epub 2024 Apr 15.
We performed a retrospective chart review of 6266 randomly selected DLBCL patients treated in the VHA nationwide between 1/1/2011 and 12/31/2021. The 3178 patients who met inclusion criteria were predominantly male (97%) and white (75%). Median age of diagnosis for Black patients was 63 years vs 69 years for the entire cohort ( < 0.001). However, patients in each race/ethnicity subgroup presented with similar rates of stage I/II and III/IV disease, IPI score, cell of origin and HIT status. Outcomes analysis revealed similar treatment, response rates, median overall survival, and 1-, 3-, and 5-year survival across all subgroups. Hispanic patients had a 21% lower risk of death (HR = 0.79) than white patients, and Black patients had no significant difference in survival (HR = 0.98). This large retrospective study shows that when standard of care therapy is given within an equal access system, short-term treatment and survival outcomes are the same for all races.
我们对 2011 年 1 月 1 日至 2021 年 12 月 31 日期间在全美退伍军人事务部(VHA)接受治疗的 6266 名随机选择的弥漫性大 B 细胞淋巴瘤(DLBCL)患者进行了回顾性图表审查。符合纳入标准的 3178 名患者主要为男性(97%)和白人(75%)。黑人患者的诊断中位年龄为 63 岁,而整个队列的诊断中位年龄为 69 岁(<0.001)。然而,每个种族/族裔亚组的患者均具有相似的 I 期/II 期和 III 期/IV 期疾病、国际预后指数(IPI)评分、细胞起源和 HIT 状态发生率。结果分析显示,所有亚组的治疗、缓解率、中位总生存期以及 1、3 和 5 年生存率均相似。与白人患者相比,西班牙裔患者的死亡风险降低了 21%(HR=0.79),而黑人患者的生存率无显著差异(HR=0.98)。这项大型回顾性研究表明,当在公平获得医疗系统内给予标准治疗时,所有种族的短期治疗和生存结果均相同。